Forum provides platform to discuss current and future management of
Gaucher disease
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme,
a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced that the
fourth annual Gaucher Leadership Forum (GLF) will take place on
September 21 and 22 in Munich, Germany. The GLF is a scientific meeting
sponsored by Genzyme that brings together more than 200 participants
from around the world, including physicians, academics, researchers and
patient organization representatives to discuss current care for
patients with Gaucher disease and the direction of future disease
management. This year’s GLF is chaired by Dr. Pram Mistry, Professor of
Pediatrics and Internal Medicine, Director of the National Gaucher
Disease Treatment Center and Chief of Pediatric
Gastroenterology/Hepatology at Yale University School of Medicine.
“The GLF is an opportunity for creative exchange of new insights and for
collaboration among members of the global Gaucher community to enhance
the care of those living with Gaucher disease, with an emphasis on
personalized medicine”
“The GLF is an opportunity for creative exchange of new insights and for
collaboration among members of the global Gaucher community to enhance
the care of those living with Gaucher disease, with an emphasis on
personalized medicine,” said Dr. Mistry. “This forum will bring into
sharp focus unmet needs in Gaucher disease and help define our vision
for the future.”
In addition to Dr. Mistry’s role as Chair of the forum, a Scientific
Steering Committee of five international experts collaborated on the
content of the meeting. The plenary presentations will highlight unmet
needs in current Gaucher disease management and working groups will
assess the current state of knowledge on key topics to develop a roadmap
for future investigations.
Genzyme’s President and Chief Executive Officer, David Meeker, M.D.,
will provide opening remarks at the meeting. “The GLF has evolved from a
local, European meeting to a global one in scope, but still driven by a
simple objective – to collaborate across our community with the common
goal of transforming the lives of patients living with Gaucher,” said
Dr. Meeker. “The momentum of ongoing research, combined with the
opportunities to improve the care of patients, make this a critical
moment for thought leaders to come together.”
Among the presenters at this year’s GLF are some of the previous winners
of the Gaucher Generation program. Since 2008, this Genzyme program has
provided annual research awards to researchers throughout the world to
stimulate and support the advancement of medical knowledge in Gaucher
disease. An independent committee of international Gaucher disease
experts reviews the submitted research proposals to select the most
meritorious applications. Later this year, Genzyme will award two “New
Investigator Awards,” with each recipient receiving an award of up to
$100,000 provided over two years, as well as one “Established
Investigator Award,” with an award of up to $150,000 also provided over
two years.
About Genzyme, a Sanofi Company
Genzyme has pioneered the development and delivery of transformative
therapies for patients affected by rare and debilitating diseases for
over 30 years. We accomplish our goals through world-class research and
with the compassion and commitment of our employees. With a focus on
rare diseases and multiple sclerosis, we are dedicated to making a
positive impact on the lives of the patients and families we serve. That
goal guides and inspires us every day. Genzyme’s portfolio of
transformative therapies, which are marketed in countries around the
world, represents groundbreaking and life-saving advances in medicine.
As a Sanofi company, Genzyme benefits from the reach and resources of
one of the world’s largest pharmaceutical companies, with a shared
commitment to improving the lives of patients. Learn more at www.genzyme.com.
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops
and distributes therapeutic solutions focused on patients’ needs. Sanofi
has core strengths in the field of healthcare with seven growth
platforms: diabetes solutions, human vaccines, innovative drugs,
consumer healthcare, emerging markets, animal health and the new
Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York
(NYSE: SNY).